... rates were 62% versus 63% ( p = 0.98), and PD rates were 21% versus 37% ( p = 0.38). Chemotherapy Gastroenteropancreatic neuroendocrine tumors Metastases FOLFOX Insulinomas For metastatic disease, systemic treatment options supported by randomized trials mainly include...

... neuroendocrine tumours (PNET) was analysed separately. These patients had received 234 lines of treatment (105 chemotherapy, 82 molecular targeted therapy, and 47 peptide receptor radionuclide therapy [PRRT]). In the G2 cohort, TTF and TTP were superior for PRRT compared with both chemotherapy and molecular...

... pancreatic neuroendocrine tumors (PanNETs), previously pretreated with chemothe-r-apy, undergoing peptide receptor radionuclide therapy (PRRT) with 177 Lu-DOTATATE. Methods: A total of 102 patients with advanced PanNETs, previously pretreated with one (67%) or several (33%) lines of chemotherapy, were...

...George Papaxoinis; Zoe Kordatou; Lynne McCallum; Magdy Nasralla; Angela Lamarca; Alison Backen; Daisuke Nonaka; Wasat Mansoor Background: Temozolomide and capecitabine (CAPTEM) chemotherapy is known to be active in patients with pancreatic neuroendocrine tumours. Objective: This retrospective...

...) of the digestive tract are rare and aggressive tumours. In localised disease the treatment is surgery. Based on expert consensus, international guidelines recommend the administration of adjuvant chemotherapy combining etoposide and platinum derivatives, justified by the high risk of metastatic relapse. However...

...Louis de Mestier; Thomas Walter; Camille Evrard; Paul de Boissieu; Olivia Hentic; Jérôme Cros; David Tougeron; Catherine Lombard-Bohas; Vinciane Rebours; Pascal Hammel; Philippe Ruszniewski Background: The combination of capecitabine (CAP) with temozolomide (TEM) chemotherapy in advanced pancreatic...

...Louis de Mestier; Thomas Walter; Hedia Brixi; Camille Evrard; Jean-Louis Legoux; Paul de Boissieu; Olivia Hentic; Jérôme Cros; Pascal Hammel; David Tougeron; Catherine Lombard-Bohas; Vinciane Rebours; Philippe Ruszniewski; Guillaume Cadiot Introduction: Although chemotherapy combining 5...

..., sunitinib, everolimus, anlotinib, or other chemotherapy regimens. The patients received S-1 at 40 mg/m 2 orally twice daily on days 1-14 and temozolomide 200 mg orally once daily on days 10-14 of a 21-day cycle. The patients were followed up for evidence of object response, toxicity, and progression-free...

... Neuroendocrine tumours Chemotherapy Treatment Prognosis Mixed tumours Neuroendocrine neoplasms (NEN) are a heterogeneous group of rare neoplasms that represent 1% of all digestive malignancies [ 1 ]. The 2017 World Health Organization classification of NENs relies on the histological grade, based...

... Conference participants Systemic chemotherapy is indicated in progressive or bulky advanced pancreatic neuroendocrine tumors (NETs) and in grade 3 (G3) neuroendocrine neoplasms (NENs) as per ENETS guidelines. Chemotherapy may be considered in NETs of other sites (lung, thymus, stomach, colon, and rectum...

...-Xavier Caroli-Bosc; Olivia Hentic Background: The best chemotherapy regimen for well- differentiated pancreatic neuroendocrine tumours (pNETs) with a Ki-67 index ≥10% is still debated. We evaluated the antitumour efficacy of various first-line chemotherapy regimens (streptozocin based, platinum based...

... Fazio Purpose: The role of chemotherapy in low-/intermediate-grade neuroendocrine tumors (NETs) is still debated. We present the results of an Italian multicenter retrospective study evaluating activity and toxicity of oxaliplatin-based chemotherapy in patients with advanced NETs. Methods: Clinical...

...) neuroendocrine carcinomas, progressive disease and undergoing chemotherapy were at particular risk of malnutrition associated with a poorer outcome. Multivariate analysis confirmed the important and highly significant role of malnutrition as an independent prognostic factor for NEN besides proliferative capacity...

..., respectively. Having either a G3 tumor or a stage IV tumor were significant prognostic factors for a shorter progression-free survival. Chemotherapy had to be discontinued in 29 patients due to side effects, of which kidney toxicity (mainly grades 1-2) was the most frequent. Conclusion: As shown in recent...

... The prognosis of metastatic atypical carcinoids is usually poor [ 15 ]. Prior studies on chemotherapy have largely been discouraging. Cisplatin + etoposide and paclitaxel may have some effect [ 7,8 ]. In 2007 a small study, however, indicated that temozolomide might be an effective substance in bronchial...

...T. Terashima; C. Morizane; N. Hiraoka; H. Tsuda; T. Tamura; Y. Shimada; S. Kaneko; R. Kushima; H. Ueno; S. Kondo; M. Ikeda; T. Okusaka Background: The chemotherapy for small-cell lung carcinoma (SCLC) has been adopted for advanced extrapulmonary neuroendocrine carcinomas (EP-NECs). The aim...

.... Neuroendocrine tumour Diagnosis Histopathology Surgery Cytoreductive surgery Biotherapy Chemotherapy Radioreceptor therapy ENETS Guidelines Neuroendocrinology 2004;80:394 424 DOI: 10.1159/000085237 Published online: April 18, 2005 Guidelines for the Diagnosis and Treatment of Neuroendocrine...

... or not), origin and extension, but also on histological differentiation and proliferative capacity. The natural history of well-differentiated tumours is often favourable without treatment and GEP endocrine tumours may remain indolent for many years. Chemotherapy may however be indicated in the presence...